ECTRIMS: First-in-Class Monoclonal Antibody Shows Promise in Phase 2 Data

Friday, October 27, 2017 | Clinical Trials , Multiple Sclerosis & Immune Disorders , Phase 3/4 Trials , Research and Publications , Biogen


Results from the Phase 2 SYNERGY trial suggest that the investigational opicinumab (Biogen) could have an increased clinical effect in patients with relapsing multiple sclerosis (MS) who had the disease for shorter periods of time. The data, presented at the 7th Joint Meeting of the ECTRIMS-ACTRIMS in Paris, also showed that opicinumab, a first-in-class monoclonal antibody directed against LINGO-1, may be beneficial in patients whose MRI results show certain brain features that suggest repair of MS lesions may be possible through remyelination. Based on the SYNERGY findings, the company also initiated its Phase 2 clinical trial AFFINITY to evaluate opicinumab as an investigational add-on therapy in people with relapsing MS. The primary endpoint of the study, Overall Response Score (ORS), is an integrated measure of both the improvement and worsening of disability over time.

Next Story

Comments

You must be logged in to leave a comment.